Evaluation of ERG responsive proteome in prostate cancer.
| Author | |
|---|---|
| Abstract |
:
Gene fusion between TMPRSS2 promoter and the ERG proto-oncogene is a major genomic alteration found in over half of prostate cancers (CaP), which leads to aberrant androgen dependent ERG expression. Despite extensive analysis for the biological functions of ERG in CaP, there is no systematic evaluation of the ERG responsive proteome (ERP). ERP has the potential to define new biomarkers and therapeutic targets for prostate tumors stratified by ERG expression. |
| Year of Publication |
:
2014
|
| Journal |
:
The Prostate
|
| Volume |
:
74
|
| Issue |
:
1
|
| Number of Pages |
:
70-89
|
| ISSN Number |
:
0270-4137
|
| URL |
:
https://doi.org/10.1002/pros.22731
|
| DOI |
:
10.1002/pros.22731
|
| Short Title |
:
Prostate
|
| Download citation |
